Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Tyra Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Habib J. Dable, Director (Form 8-K filed 2026-04-17). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bvf Partners L P/Il (filed 2026-09-21).
Who is behind it
Tyra Biosciences, Inc.: incorporated in Delaware; business address in Carlsbad, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-09-21).
Officers and directors, each with the role and the filing that names them:
- Todd Harris, Ph.D.: Executive Officer, Director (Form D, 2024-02-13)
- Alan Fuhrman: Executive Officer (Form D, 2024-02-13)
- Daniel Bensen: Executive Officer (Form D, 2024-02-13)
- Hiroomi Tada, M.D., Ph.D.: Executive Officer (Form D, 2024-02-13)
- Isan Chen, M.D.: Director (Form D, 2024-02-13)
- Gilla Kaplan, Ph.D.: Director (Form D, 2024-02-13)
- Nina Kjellson: Director (Form D, 2024-02-13)
- Melissa McCracken, Ph.D.: Director (Form D, 2024-02-13)
- Robert More: Director (Form D, 2024-02-13)
- Jake Simson, Ph.D.: Director (Form D, 2024-02-13)
- Sid Subramony, Ph.D.: Director (Form D, 2024-02-13)
- Rehan Verjee: Director (Form D, 2024-02-13)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-09-21 | Bvf Partners L P/Il | 6.1% |
| Schedule 13G, 2026-09-17 | Paradigm Biocapital Advisors LP | 5.8% |
| Schedule 13D/A, 2026-09-17 | Ra Capital Management, L.P. | 19.9% |
| Schedule 13G/A, 2026-08-14 | Farallon Capital Management, L.L.C. | 0% |
| Schedule 13G/A, 2026-08-14 | Nextech Vi Oncology Scsp | 6% |
| Schedule 13G, 2026-07-30 | Blackrock, Inc. | 5% |
| Schedule 13G/A, 2026-05-15 | Commodore Capital LP | 4.2% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 7.2% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-17 | Habib J. Dable | Director | appointed | |
| Form 8-K, 2026-04-02 | Julia Rueb | Chief Financial Officer | appointed | 2026-04-01 |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-02-13 | $200M | $200M |
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/tyra-biosciencesLast updated 2026-10-18
Primary record: Schedule 13G, 2026-09-21 · Form D, 2024-02-13 · Form 8-K, 2026-04-17 · Form 8-K, 2026-04-02
Who owns Tyra Biosciences, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/tyra-biosciences